Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of pharmaceutical composition for preventing and treating covid-19 and preparation method thereof

A technology for COVID-19 and Mycobacterium vaccae, applied in the field of medicine, can solve the problems of large adverse reactions of exogenous IFN and inaccurate actual therapeutic effect, and achieve the purpose of improving the level of endogenous interferon and inhibiting the replication of viral RNA. , the effect of promoting expectoration

Active Publication Date: 2022-02-01
THE FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, in the latest diagnosis and treatment plan ("Diagnosis and Treatment Plan for Pneumonia Infected by Novel Coronavirus (Trial Version 5 and 6)" issued by the National Health and Health Commission on January 27, 2020), nebulized inhalation of α-IFN (500 mg per adult for adults) is recommended. 10,000 U, add 2ml of sterile water for injection, twice a day), but its actual therapeutic effect is still uncertain. Consider its high cost and whether aerosol inhalation of α-IFN can reach the lower respiratory tract and lung tissue

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pharmaceutical composition for preventing and treating covid-19 and preparation method thereof
  • A kind of pharmaceutical composition for preventing and treating covid-19 and preparation method thereof
  • A kind of pharmaceutical composition for preventing and treating covid-19 and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Take 22.5 micrograms of microcalorie x2 + 10ml of normal saline, and inhale it by jet nebulization at an oxygen flow rate of 5L / min (see attached figure 1 ), until all the liquid medicine is absorbed (about 20 minutes), Qd, 10 days / course of treatment; spray salbutamol sulfate aerosol, that is, "Ventolin" 3 sprays before nebulization.

Embodiment 2

[0032] Make 25 micrograms / bottle of microcalorie × 2 bottles + salbutamol into 10ml of normal saline aseptic mixture at a weight ratio of 1:50-200, and inhale it by jet nebulization at an oxygen flow rate of 5L / min until all the liquid is inhaled ( about 20 minutes), Qd, 10 days / course of treatment.

Embodiment 3

[0034] Make 25 micrograms / bottle of microcalorie × 2 bottles + salbutamol into 5ml normal saline sterilized mixed solution at a weight ratio of 1:50-200, and make an aerosol separately, 1 bottle per day, Qd, 10 days / course of treatment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medical technology, and in particular relates to a pharmaceutical composition for preventing and treating COVID-19 (a disease caused by a novel coronavirus) and a preparation method thereof. The pharmaceutical composition comprises Mycobacterium vaccae and salbutamol sulfate for injection The active ingredient, its composition and weight ratio are: mycobacterium vaccae for injection: salbutamol sulfate is 1:50-200. The medicine made from the pharmaceutical composition can be treated by aerosol inhalation. Through short-term aerosol inhalation, providing patients with this special-purpose medicine can improve patient compliance, make medication convenient for patients, and reduce medical expenses. . The pharmaceutical composition for the prevention and treatment of COVID-19 described in the present invention can not only effectively prevent and treat COVID-19, reduce the patient's conversion to severe or critical illness, shorten the average time of negative nucleic acid conversion by about 4 days, and shorten the treatment time accordingly. The non-specific prevention and treatment of other respiratory viral infections provides new ways and solutions for the clinical prevention and treatment of COVID‑19 and respiratory viral infections.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition for preventing and treating COVID-19 (a disease caused by a novel coronavirus) and a preparation method thereof. Background technique [0002] Interferon (IFN) is the most important and possibly the only natural non-specific antiviral natural component in the body. IFN is currently the most important non-specific antiviral component found and recognized in the body, which is divided into type I (IFN-β and IFN-α), type II (IFN-γ) and type III (IFN-λ1, IFN- λ2, IFN-λ3) IFN. After IFN is produced, it activates the intracellular JAK-STAT pathway at the infected site, regulates the transcription of hundreds of related effector antiviral genes (ISGs), thereby inhibiting virus proliferation, promoting apoptosis of infected cells, and allowing uninfected cells to enter Antiviral status, IFN can also promote the maturation of various innate immu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/72A61K9/12A61K31/137A61K35/74A61P31/14
CPCA61K9/0078A61K31/137A61K35/74A61P31/14A61K9/12A61K2300/00
Inventor 李超乾林艳荣
Owner THE FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com